Cascade Medical Enterprises, LLC Announces the Sale of Their Orthopedic Business
WAYNE, N.J., Jan. 6, 2012 /PRNewswire/ -- Cascade Medical Enterprises, LLC (CME), a leading company with proprietary platelet-rich plasma (PRP) and platelet-rich fibrin matrix (PRFM) technology for use in orthopedic therapeutic applications in soft tissue and bone repair, announced the sale of their technology to Musculoskeletal Transplant Foundation (MTF) and distribution by ConMed Linvatec for the worldwide orthopedic, dental, and wound care markets.
CME has had a long collaborative US distribution relationship with MTF for the sale of their products in the sports medicine market. This collaboration has enabled the companies to achieve a formative market presence establishing CME as a science-based provider of a unique technology for the collection, preparation, and delivery of an autologous blood-derived platelet and fibrin biologic. The CME technology has been developed into procedure specific systems and kits, marketed as the CASCADE® System. The key proprietary aspects of the CASCADE® technology are the ability to produce liquid, gel, and membrane formats for the PRP and PRFM to meet the needs of the specific procedure technique requirements.
The CASCADE® System is an FDA 510(k) cleared device that is designed to be used for the safe and rapid preparation of autologous PRP from a small sample of blood at the patient point of care. The PRP can be mixed with autograft and allograft bone prior to the application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
Autologous PRP and PRFM are biologic preparations that are derived from the patient's own blood. Platelets are known to contain growth factors that stimulate the body's natural healing of soft tissue and bone. The collection and concentration of these factors from a small sample of blood using systems that are safe, easy to use, and designed to maximize performance are unique to the CA